AdvanCell, a clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, announced $18M in Australian Federal Government Funding from the Medical Research Future Fund (MRFF) Frontiers Initiative for ‘Defeating Prostate...
an ongoing Phase 2 trial in patients with multiple myeloma (MM) undergoing autologous stem cell transplant (ASCT; NCT05561751). Clinical trial results for this study are expected in Q4 2025. Current Evaluating Potential Indication Expansions – In...
A landmark clinical trial co-led by Hospital for Special Surgery (HSS) has found that blocking inflammation with the drug certolizumab significantly reduces the risk of serious adverse pregnancy outcomes in women with antiphospholipid syndrome...
Novotech, a globally recognized full-service biotech specialist clinical research organization (CRO), announced today that affiliates of GIC and Temasek have signed binding agreements to acquire a significant stake in the company, with the...
Therapeutics, Inc. ("Pykus" or the "Company") announced that it has completed enrollment of its pilot study (PYK-2101-RD001) in Australia. The study is evaluating the use of Pykus' proprietary, lead product candidate, PYK-2101, a focal hydrogel...
IFF Pharma Solutions, a global leader in polymer innovations, announced the launch of Low Nitrite METHOCEL™ hydroxypropyl methylcellulose (HPMC), a range of low nitrite cellulose ethers developed to reduce the risk of nitrosamine formation in...
have concluded that you may proceed with your proposed clinical investigation of fenretinide phospholipid suspension (ST-001) for small cell lung cancer." This decision marks a significant step forward in SciTech's mission to address unmet needs in...
Hello Heart, the digital leader in preventive heart health, today introduced Hello Heart Pill Box, a proprietary smart pill box designed to improve medication adherence. This addition to Hello Heart’s suite of heart health tools, including its...
George Clinical, a leading clinical research organization (CRO) operating worldwide, is pleased to announce it has rebranded to become Emerald Clinical Trials. This strategic name change underscores the company's well-established position as a...
Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch1 of Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial). Glenmark's Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25...
Cognito Therapeutics, a pioneering neurotechnology company developing disease-modifying therapies for neurodegenerative diseases, today announced new data from its OVERTURE feasibility trial at the AD/PD™ 2025. The results showed that Spectris™,...
PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo, President: Junichiro Ishizuka) has successfully developed a novel synthetic peptide called "KGF alternative- peptide (FGFR2b agonist)" which is functionally equivalent to recombinant keratinocyte...
Hanmi Pharmaceutical's combination therapy for Obstructive Prostatic Growth (OPG) caused by Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED), Gugutams, is entering the Mexican market under the local brand name "Aditams." Hanmi...
ELIQUENT Life Sciences (ELIQUENT), a global regulatory, quality, and safety consulting firm, today announced the acquisition of Truliant Consulting (Truliant), a leading pharmacovigilance, risk management, and regulatory compliance advisory firm....
Bruin Biometrics LLC, a medical technology platform company that provides digital solutions for pressure injury prevention and management to health systems in the U.S. and U.K., announced it has been named by Fast Company as one of the World's 10...
Attendees at this year's American College of Foot and Ankle Surgeons Annual Meeting in Phoenix, Ariz. will be the first to see Medline UNITE's new Synthetic Ligament Augmentation implant. The intelligently designed solution provides the next...
Pint Pharma and PharmaEssentia announced that ANVISA (Brazilian Health Regulatory Agency) has approved BESREMi® (ropeginterferon alfa-2b) for the treatment of adult patients with Polycythemia Vera (PV). Polycythemia Vera (PV) is a rare, chronic,...
Secretome Therapeutics, a pioneering company in the field of regenerative medicine, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to STM-01, the company’s neonatal cardiac progenitor cell (nCPC)...
President: Kyoko Deguchi), and Cyfuse Biomedical K.K. announce the successful development of a new production technology(*1) for the commercialization of the field of regenerative and cell therapy. This achievement is the result of a strategic...
Niagen Bioscience, Inc. the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today confirmed it has changed its corporate name to Niagen Bioscience, Inc. (“Niagen Bioscience” or the...
